In vivo performance and biocompatibility of the MagScrew ventricular assist device.
In vivo performance and biocompatibility of the MagScrew ventricular assist device.
复制标题
MagScrew 心室辅助装置的体内性能和生物相容性。
DOI：
10.1097/01.mat.0000084107.46300.21
复制
发表时间：
2003
期刊：
影响因子：
--
通讯作者：
Smith,William
中科院分区：
文献类型：
--
作者：
Schenk,Soren;Weber,Stephan;Luangphakdy,Viviane;Flick,ChristineR;Chen,Ji-Feng;Inoue,Masahiro;KopcakJr,MichaelW;Ootaki,Yoshio;Doi,Kazuyoshi;Dessoffy,Raymond;Hirschman,GordonB;Vitale,NicholasG;ChapmanJr,PeterA;Smith,William
目前可用的心室辅助装置（VAD）在长期耐久性和血液相容性方面具有局限性。我们评估了脉动MagScrew VAD原型的体内血流动力学性能和生物相容性。该器械由致动器、血泵外壳、隔膜、推板和生物瓣膜组成。它的蛋白质涂层（“生物化”）血液接触表面抑制凝块形成。致动器的运动部件之间的力通过磁性传递，消除了摩擦和磨损的主要来源。该泵被动填充，并且对预载高度敏感。该器械分别植入3头小牛体内90、10和57天。术后未给予抗凝剂。在每次实验的整个过程中，该器械的功能没有任何技术问题，平均器械流量范围为5.4 - 9.0 L/min。前两只小牛的尸检显示没有栓塞迹象，器械的血液接触表面清洁。第三项实验因人工瓣膜心内膜炎伴感染性栓塞而复杂化，在泵中发现了一些小的沉积物。总之，MagScrew VAD在3头小牛中研究了10-90天，证明了高水平的性能和生物相容性。目前正在大力开发，以使该器械进入临床前准备状态，从而为外科医生提供永久植入的VAD选择。
Currently available ventricular assist devices (VADs) have limitations in long-term durability and blood compatibility. We evaluated a prototype of a pulsatile MagScrew VAD for in vivo hemodynamic performance and biocompatibility. The device is composed of an actuator, blood pump housing, diaphragm, pusher plate, and bioprosthetic valves. Its protein-coated (“biolized”) blood-contacting surface inhibits clot formation. Forces between moving parts of the actuator are transmitted magnetically, eliminating a primary source of friction and wear. The pump fills passively and is highly preload sensitive. The device was implanted into three calves for 90, 10, and 57 days, respectively. No anticoagulants were given postoperatively. The device functioned without technical problems during the entire course of each experiment, with mean device flow ranging between 5.4 and 9.0 L/min. Autopsy of the first two calves revealed no sign of embolization and clean blood-contacting surfaces of the devices. The third experiment was complicated by a prosthetic valve endocarditis with infectious embolization, and a few small depositions were found in the pump. In conclusion, the MagScrew VAD has demonstrated a high level of performance and biocompatibility in three calves studied for 10–90 days. Vigorous development is in progress to bring this device to preclinical readiness and thus provide surgeons with the VAD of choice for permanent implantation.